Autopsy report · NCT00227656

Capecitabine and Pegylated Interferon Alfa-2a in Treating Patients With Recurrent or Progressive Brain Metastases Due to Breast Cancer

“Study slow to accrue.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 2 months before it stopped.
• 2 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

M.D. Anderson Cancer Center

Sponsor type

University, hospital or other

Conditions

Breast Cancer; Metastatic Cancer

Interventions

PEG-interferon alfa-2a; Capecitabine

Participants

2

Sites

4

Countries

United States

Trials that died the same way

• Study in Adult Subjects Undergoing Posterolateral Thoracotomy
  “Slow study enrollment” (74% match in meaning)
• Steroid Delivery to the Frontal Sinus Opening With a Bioabsorbable Implant vs. a Bioabsorbable Nasal Dressing
  “Study enrollment was too slow to complete the study in a reasonable time” (74% match in meaning)
• OrthoPulse Gen 2 Initial Device Evaluation and Assessment of Clinical Effectiveness (CA)
  “Study stopped because slow enrolment.” (72% match in meaning)
• Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies
  “Study terminated due to slow accrual.” (70% match in meaning)
• LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
  “Study was terminated due to slow accrual.” (69% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.